Pharming Group reports first quarter 2025 financial results and provides business update
Financial updatesPharming Group N.V. presents its preliminary unaudited financial report for the three months ended March 31, 2025.
Pharming Group to report first quarter 2025 financial results on May 8
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period ended March 31, on Thursday, May 8, 2025.
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
Financial updatesPharming Group N.V. announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”).
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2024.
Pharming Group to report fourth quarter and full year 2024 financial results on March 13
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended December 31, on Thursday, March 13, 2025.
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
Financial updatesPharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent.
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
Financial updatesOn December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the shareholders of Abliva AB (publ) (“Abliva”) to tender all their shares in Abliva to Pharming at a price of SEK 0.45 in cash per share (the “Offer”). An offer document relating to the Offer was published on January 15, 2025.
Pharming announces public cash offer to the shareholders of Abliva AB
Financial updatesPharming Group N.V. today announced a recommended public cash offer to the shareholders of Abliva AB (“Abliva”) to acquire all issued and outstanding shares of Abliva.
Pharming Group reports third quarter 2024 financial results and provides business update
Financial updatesPharming Group N.V. presents its preliminary, unaudited financial report for the three months ended September 30, 2024.
Pharming Group to report third quarter 2024 financial results on October 24
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.